Login to Your Account

Clinic Roundup

Friday, May 11, 2012

• Clovis Oncology Inc., of Boulder, Colo. received notification from an independent data monitoring committee that approximately 65 percent of patients in its LEAP pivotal trial of CP-4126 for metastatic pancreatic cancer have been classified as hENT1-low. Clovis licensed CP-4126 from Clavis Pharma ASA, of Oslo, Norway in 2009.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription